In the same time, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) as gefitinib emerged as an accepted treatment in second- or third-line setting in NSCLC (Pfister et al, 2004). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.